NCT01990105

Brief Summary

FINFIB 2 is an observational investigator-driven study that seeks to examine current treatment practice for atrial fibrillation in Finland. The investigators hypothesis is that the treatment of atrial fibrillation has improved since the introduction of new antiarrhythmic drugs and anticoagulants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,013

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2013

Shorter than P25 for all trials

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

November 15, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 21, 2013

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2014

Completed
Last Updated

March 9, 2015

Status Verified

March 1, 2015

Enrollment Period

Same day

First QC Date

November 15, 2013

Last Update Submit

March 6, 2015

Conditions

Atrial Fibrillation

Keywords

atrial fibrillationanticoagulationantiarrhythmic medicationCHA2DS2VASc scoreHAS-BLED scoreCHADS2 score

Outcome Measures

Primary Outcomes (1)

  • Adherence to current atrial fibrillation treatment guidelines

    All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included for assessment of the adherence of their treatment to current guidelines.

    Data collected during the ER visit

Study Arms (1)

Patients with AF in the ER

All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study data will be obtained in the form of a cross-section sampling over two weeks. All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included. The estimated number of patients is about 1000.

You may qualify if:

  • All adult patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Helsinki University Central Hospital

Helsinki, Finland

Location

Kuopio University Hospital

Kuopio, Finland

Location

Oulu University Hospital

Oulu, Finland

Location

Tampere University Hospital

Tampere, Finland

Location

Turku University Hospital

Turku, Finland

Location

Related Publications (1)

  • Penttila T, Makynen H, Hartikainen J, Hyppola H, Lauri T, Lehto M, Lund J, Raatikainen MJP; FinFib2 investigators. Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation - a prospective nationwide cohort. Scand J Trauma Resusc Emerg Med. 2017 Aug 15;25(1):81. doi: 10.1186/s13049-017-0424-7.

    PMID: 28810904DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pekka Raatikainen, MD, PhD

    Heart Center Tampere Univerisity Hospital

    STUDY CHAIR

  • Juha Hartikainen, MD

    Kuopio University Hospital

    PRINCIPAL INVESTIGATOR

  • Timo Lauri, MD

    Oulu University Hospital

    PRINCIPAL INVESTIGATOR

  • Mika Lehto, MD

    Helsinki University Central Hospital

    PRINCIPAL INVESTIGATOR

  • Markku Mäkijärvi, MD

    Helsinki University Central Hospital

    PRINCIPAL INVESTIGATOR

  • Juha Lund, MD

    Turku University Hospital

    PRINCIPAL INVESTIGATOR

  • Heikki Mäkynen, MD

    Heart Center Tampere University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2013

First Posted

November 21, 2013

Study Start

November 1, 2013

Primary Completion

November 1, 2013

Study Completion

April 1, 2014

Last Updated

March 9, 2015

Record last verified: 2015-03

Locations

FI(5)